Literature DB >> 16151858

A novel homozygous missense mutation in FGF23 causes Familial Tumoral Calcinosis associated with disseminated visceral calcification.

Ilana Chefetz1, Raoul Heller, Assimina Galli-Tsinopoulou, Gabriele Richard, Bernd Wollnik, Margarita Indelman, Friederike Koerber, Orit Topaz, Reuven Bergman, Eli Sprecher, Eckhard Schoenau.   

Abstract

Hyperphosphatemic Familial Tumoral Calcinosis (HFTC; MIM211900) is a rare autosomal recessive disorder characterized by the progressive deposition of calcified masses in cutaneous and subcutaneous tissues, associated with elevated circulating levels of phosphate. The disease was initially found to result from mutations in GALNT3 encoding a glycosyltransferase. However, more recently, the S71G missense mutation in FGF23, encoding a potent phosphaturic protein, was identified in two families. In the present report, we describe a second mutation in FGF23 underlying a severe case displaying calcifications of cutaneous and numerous extracutaneous tissues. The mutation (M96T) was found to affect a highly conserved methionine residue at position 96 of the protein. These observations illustrate the extent of genetic and phenotypic heterogeneity in HFTC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16151858     DOI: 10.1007/s00439-005-0026-8

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  20 in total

Review 1.  Molecular pathogenesis of hypophosphatemic rickets.

Authors:  Suzanne M Jan de Beur; Michael A Levine
Journal:  J Clin Endocrinol Metab       Date:  2002-06       Impact factor: 5.958

Review 2.  Proposal for a pathogenesis-based classification of tumoral calcinosis.

Authors:  D Smack; S A Norton; J E Fitzpatrick
Journal:  Int J Dermatol       Date:  1996-04       Impact factor: 2.736

3.  A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis.

Authors:  Tobias Larsson; Xijie Yu; Siobhan I Davis; Mohamad S Draman; Sean D Mooney; Michael J Cullen; Kenneth E White
Journal:  J Clin Endocrinol Metab       Date:  2005-02-01       Impact factor: 5.958

4.  A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive.

Authors:  Shoji Ichikawa; Kenneth W Lyles; Michael J Econs
Journal:  J Clin Endocrinol Metab       Date:  2005-02-01       Impact factor: 5.958

5.  Bone densities and bone size at the distal radius in healthy children and adolescents: a study using peripheral quantitative computed tomography.

Authors:  C M Neu; F Manz; F Rauch; A Merkel; E Schoenau
Journal:  Bone       Date:  2001-02       Impact factor: 4.398

6.  Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23.

Authors: 
Journal:  Nat Genet       Date:  2000-11       Impact factor: 38.330

Review 7.  The phosphatonin pathway: new insights in phosphate homeostasis.

Authors:  Susan C Schiavi; Rajiv Kumar
Journal:  Kidney Int       Date:  2004-01       Impact factor: 10.612

8.  Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis.

Authors:  Orit Topaz; Daniel L Shurman; Reuven Bergman; Margarita Indelman; Paulina Ratajczak; Mordechai Mizrachi; Ziad Khamaysi; Doron Behar; Dan Petronius; Vered Friedman; Israel Zelikovic; Sharon Raimer; Arieh Metzker; Gabriele Richard; Eli Sprecher
Journal:  Nat Genet       Date:  2004-05-09       Impact factor: 38.330

Review 9.  A case of familial tumoral calcinosis in a neonate and review of the literature.

Authors:  Elias P Polykandriotis; Florenz K Beutel; Raymund E Horch; Jörg Grünert
Journal:  Arch Orthop Trauma Surg       Date:  2004-08-31       Impact factor: 3.067

10.  Tumoral calcinosis--an unrecognized disease.

Authors:  S McClatchie; A D Bremner
Journal:  Br Med J       Date:  1969-01-18
View more
  40 in total

Review 1.  The dualistic role of vitamin D in vascular calcifications.

Authors:  M Shawkat Razzaque
Journal:  Kidney Int       Date:  2010-10-20       Impact factor: 10.612

2.  A Phex mutation in a murine model of X-linked hypophosphatemia alters phosphate responsiveness of bone cells.

Authors:  Shoji Ichikawa; Anthony M Austin; Amie K Gray; Michael J Econs
Journal:  J Bone Miner Res       Date:  2012-02       Impact factor: 6.741

3.  Dietary phosphate restriction normalizes biochemical and skeletal abnormalities in a murine model of tumoral calcinosis.

Authors:  Shoji Ichikawa; Anthony M Austin; Amie K Gray; Matthew R Allen; Michael J Econs
Journal:  Endocrinology       Date:  2011-10-18       Impact factor: 4.736

Review 4.  Disorders of phosphate homeostasis and tissue mineralisation.

Authors:  Clemens Bergwitz; Harald Jüppner
Journal:  Endocr Dev       Date:  2009-06-03

5.  Phenotypic and Genotypic Characterization and Treatment of a Cohort With Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome.

Authors:  Mary Scott Ramnitz; Pravitt Gourh; Raphaela Goldbach-Mansky; Felasfa Wodajo; Shoji Ichikawa; Michael J Econs; Kenneth E White; Alfredo Molinolo; Marcus Y Chen; Theo Heller; Jaydira Del Rivero; Patricia Seo-Mayer; Bita Arabshahi; Malaka B Jackson; Sarah Hatab; Edward McCarthy; Lori C Guthrie; Beth A Brillante; Rachel I Gafni; Michael T Collins
Journal:  J Bone Miner Res       Date:  2016-09-20       Impact factor: 6.741

6.  A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis.

Authors:  Shoji Ichikawa; Erik A Imel; Mary L Kreiter; Xijie Yu; Donald S Mackenzie; Andrea H Sorenson; Regina Goetz; Moosa Mohammadi; Kenneth E White; Michael J Econs
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

7.  A case of familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features.

Authors:  C E Dumitrescu; M H Kelly; A Khosravi; T C Hart; J Brahim; K E White; E G Farrow; M H Nathan; M D Murphey; M T Collins
Journal:  Osteoporos Int       Date:  2008-11-04       Impact factor: 4.507

8.  Defective O-glycosylation due to a novel homozygous S129P mutation is associated with lack of fibroblast growth factor 23 secretion and tumoral calcinosis.

Authors:  Clemens Bergwitz; Santanu Banerjee; Hilal Abu-Zahra; Hiroshi Kaji; Akimitsu Miyauchi; Toshitsugu Sugimoto; Harald Jüppner
Journal:  J Clin Endocrinol Metab       Date:  2009-10-16       Impact factor: 5.958

9.  Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression.

Authors:  Shoji Ichikawa; Andrea H Sorenson; Anthony M Austin; Donald S Mackenzie; Timothy A Fritz; Akira Moh; Siu L Hui; Michael J Econs
Journal:  Endocrinology       Date:  2009-02-12       Impact factor: 4.736

Review 10.  Molecular pathology of the fibroblast growth factor family.

Authors:  Pavel Krejci; Jirina Prochazkova; Vitezslav Bryja; Alois Kozubik; William R Wilcox
Journal:  Hum Mutat       Date:  2009-09       Impact factor: 4.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.